These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 10986002)

  • 1. Safety of long-term treatment with tiagabine.
    Fakhoury T; Uthman B; Abou-Khalil B
    Seizure; 2000 Sep; 9(6):431-5. PubMed ID: 10986002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of twice- and three times daily tiagabine for the adjunctive treatment of partial seizures in refractory patients with epilepsy: an open label, randomised, parallel-group study.
    Biraben A; Beaussart M; Josien E; Pestre M; Savet JF; Schaff JL; Tourniaire D; Sevestre M; Renault-Djouadi J
    Epileptic Disord; 2001 Jun; 3(2):91-100. PubMed ID: 11431171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of tiagabine monotherapy on cognition and mood in adult patients with chronic partial epilepsy.
    Aikiä M; Jutila L; Salmenperä T; Mervaala E; Kälviäinen R
    Epilepsy Behav; 2006 Jun; 8(4):750-5. PubMed ID: 16647884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures. Northern European Tiagabine Study Group.
    Kälviäinen R; Brodie MJ; Duncan J; Chadwick D; Edwards D; Lyby K
    Epilepsy Res; 1998 Mar; 30(1):31-40. PubMed ID: 9551842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of adjunctive therapy with tiagabine in mentally disabled patients with epilepsy.
    Chmielewska B; Stelmasiak Z
    Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):226-36. PubMed ID: 12898928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tiagabine: a new therapeutic option for people with intellectual disability and partial epilepsy.
    Kälviäinen R
    J Intellect Disabil Res; 1998 Dec; 42 Suppl 1():63-7. PubMed ID: 10030435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability of tiagabine: a prospective open-label study.
    Bauer J; Bergmann A; Reuber M; Stodieck SR; Genton P
    Epileptic Disord; 2002 Dec; 4(4):257-60. PubMed ID: 12600812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term safety of using tiagabine in epilepsy].
    Kozik A
    Neurol Neurochir Pol; 2000; 34 Suppl 7():17-22; discussion 22-3. PubMed ID: 11253488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.
    Husain A; Chung S; Faught E; Isojarvi J; McShea C; Doty P
    Epilepsia; 2012 Mar; 53(3):521-8. PubMed ID: 22372628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the cognitive effects of tiagabine and carbamazepine as monotherapy in newly diagnosed adult patients with partial epilepsy: pooled analysis of two long-term, randomized, follow-up studies.
    Aikiä M; Jutila L; Salmenperä T; Mervaala E; Kälviäinen R
    Epilepsia; 2006 Jul; 47(7):1121-7. PubMed ID: 16886974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tiagabine for epilepsy.
    Med Lett Drugs Ther; 1998 Apr; 40(1024):45-6. PubMed ID: 9580745
    [No Abstract]   [Full Text] [Related]  

  • 12. Tiagabine-related non-convulsive status epilepticus in partial epilepsy: three case reports and a review of the literature.
    Kellinghaus C; Dziewas R; Lüdemann P
    Seizure; 2002 Jun; 11(4):243-9. PubMed ID: 12027571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seizure activity and off-label use of tiagabine.
    Flowers CM; Racoosin JA; Kortepeter C
    N Engl J Med; 2006 Feb; 354(7):773-4. PubMed ID: 16481654
    [No Abstract]   [Full Text] [Related]  

  • 14. [Open study with tiagabine in partial epilepsy].
    Arroyo S
    Rev Neurol; 2000 Oct 16-31; 31(8):728-32. PubMed ID: 11082879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Various Aspects of Tiagabine Effectiveness as Add-on Therapy in Patients with Refractory Epilepsy.
    Viteva E; Zahariev Z
    Folia Med (Plovdiv); 2020 Mar; 62(1):59-64. PubMed ID: 32337898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Determinants of tiagabine (TGB) efficacy and safety. A Polish multicenter study of 1307 patients with focal epilepsy].
    Kozik A; Krause M
    Neurol Neurochir Pol; 2003; 37(3):537-46. PubMed ID: 14593750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tiagabine: the safety landscape.
    Leppik IE
    Epilepsia; 1995; 36 Suppl 6():S10-S13. PubMed ID: 8595787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tiagabine therapy for complex partial seizures. A dose-frequency study. The Tiagabine Study Group.
    Sachdeo RC; Leroy RF; Krauss GL; Drake ME; Green PM; Leppik IE; Shu VS; Ringham GL; Sommerville KW
    Arch Neurol; 1997 May; 54(5):595-601. PubMed ID: 9152116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Status epilepticus and tiagabine therapy revisited.
    Koepp MJ; Edwards M; Collins J; Farrel F; Smith S
    Epilepsia; 2005 Oct; 46(10):1625-32. PubMed ID: 16190934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised open-label study of tiagabine given two or three times daily in refractory epilepsy.
    Arroyo S; Boothman BR; Brodie MJ; Duncan JS; Duncan R; Nieto M; Calandre EP; Forcadas I; Crawford PM
    Seizure; 2005 Mar; 14(2):81-4. PubMed ID: 15694559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.